Product Identification

Product Name

3-Ethyl-2-methyl-5-(morpholin-4-ylmethyl)-1,5,6,7-tetrahydroindol-4-one

Synonyms

(+/-)-Molindone
3-Ethyl-1,5,6,7-tetrahydro-2-methyl-5-(4-morpholinylmethyl)-4H-indol-4-one
3-Ethyl-2-methyl-5-(morpholin-4-ylmethyl)-1,5,6,7-tetrahydroindol-4-one
3-Ethyl-6,7-dihydro-2-methyl-5-(morpholinomethyl)indol-4(5H)-one

CAS

7416-34-4

Formula

C16H24N2O2

Molecular Weight

276.38

RTECS

NM3300000

RTECS Class

Drug; Human Data

Merck

12,6315

Beilstein/Gmelin

413239

Physical and Chemical Properties

Appearance

Crystals.

Solubility in water

Insoluble

Melting Point

180 - 181

pKa/pKb

6.83 (pKa)

Usage

Medication.

First Aid Measures

Ingestion

Seek medical attention. If individual is drowsy or unconscious, do not give anything by mouth; place individual on the left side with the head down. Contact a physician, medical facility, or poison control center for advice about whether to induce vomiting. If possible, do not leave individual unattended.

Inhalation

If symptoms develop, move individual away from exposure and into fresh air. If symptoms persist, seek medical attention. If breathing is difficult, administer oxygen. Keep person warm and quiet; seek immediate medical attention.

Skin

Flush skin with plenty of soap and water for at least 15 minutes while removing contaminated clothing and shoes.

Eyes

If symptoms develop, immediately move individual away from exposure and into fresh air. Flush eyes gently with water for at least 15 minutes while holding eyelids apart; seek immediate medical attention.

Handling and Storage

Storage

Keep in a cool, dry, dark location in a tightly sealed container or cylinder. Keep away from incompatible materials, ignition sources and untrained individuals. Secure and label area. Protect containers/cylinders from physical damage.

Handling

All chemicals should be considered hazardous. Avoid direct physical contact. Use appropriate, approved safety equipment. Untrained individuals should not handle this chemical or its container. Handling should occur in a chemical fume hood.

Hazards Identification

Inhalation

Tachypnea occurred in a patient with neuroleptic malignant syndrome previously exposed to other neuroleptics.

Ingestion

Dry mouth, contributing to dysphagia, has been reported during molindone therapy. Weight gain and loss during therapeutic use have occurred.

Exposure Controls/Personal Protection

Personal Protection

Chemical splash goggles in compliance with OSHA regulations are advised; however, OSHA regulations also permit other type safety glasses. Whre chemical resistant gloves. To prevent repeated or prolonged skin contact, wear impervious clothing and boots.

Respirators

Use NIOSH/MSHA approved respirator appropriate for exposure of concern.

Exposure Effects

Hyperpyrexia, abnormally low blood pressure and shallow, rapid respirations have occurred with therapeutic use in patients previously exposed to neuroleptics. neuroleptic malignant syndrome (symptoms include: fever, rigidity, autonomic instability, altered mental status, rhabdomyolysis and diaphoresis) has been reported in one therapeutically dosed patient previously exposed to neuroleptics. Extrapyramidal effects (rigidity, tremor, akathisia, major tonic spasms and tardive dyskinesia) have been reported with therapeutic use and may occur in overdose.

Fire Fighting Measures

Fire Fighting

Wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Use agent most appropriate to extinguish fire.

Accidental Release Measures

Small spills/leaks

Evacuate area and ventilate. Wear protective equipment. If required, use an inert absrobent. Sweep up and place in an appropriate container for disposal. Wash contaminated surfaces.

Stability and Reactivity

Stability

No data.

Incompatibilities

Strong oxidizing agents.